Illumina solutions in next-generation sequencing (NGS) and microarray technologies deliver fast, accurate information that can guide choices and transform lives at multiple touchpoints along the reproductive and genetic health journey.

The verifi Prenatal Test was developed by, and its performance characteristics were determined by Verinata Health, Inc. a wholly owned subsidiary of Illumina, Inc. The VHI laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.